Relationship between serum microRNA-1 and microRNA-155 expression and disease severity and prognosis of acute cerebral infarction / 中国基层医药

ABSTRACT

Objective:To investigate the relationship between serum microRNA-1 (miR-1) and microRNA-155 (miR-155) expression and disease severity and prognosis of acute cerebral infarction (ACI) in patients.Methods:A total of 173 patients with ACI who received treatment in Taizhou Municipal Hospital between April 2018 and August 2019 were included in this study. These patients were divided into mild ( n = 78), moderate ( n = 54) and severe ( n = 41) groups according to the National Institutes of Health Stroke Scale (NIHSS) score. A total of 180 patients who concurrently received physical examination were included in the control group. Serum miR-1 and miR-155 expression was determined in all participants using quantitative reverse transcription-polymerase chain reaction. The included patients were divided into poor prognosis and good prognosis groups according to modified Rankin scale score within 90 days after treatment. The efficacy of serum miR-1 and miR-155 expression in the prediction of ACI prognosis and the risk factors for poor prognosis of ACI were evaluated. Results:The history of hypertension, systolic blood pressure, diastolic blood pressure, total cholesterol, low density lipoprotein cholesterol, serum miR-1 and miR-155 expression in the study group were 56.65% (98/173), (134.02 ± 27.35) mmHg, (88.45 ± 9.52) mmHg, (3.78 ± 0.82) mmol/L, (2.08 ± 0.73) mmol/L, (2.07 ± 0.37) and (1.56 ± 0.32), respectively, which were significantly higher than those in the control group [39.44% (71/180), (119.37 ± 22.14) mmHg, (81.46 ± 14.13) mmHg, (3.59 ± 0.68) mmol/L, (1.74 ± 0.69) mmol/L, (1.01 ± 0.22), (1.02 ± 0.24)], high density lipoprotein cholesterol in the study group was significantly lower than that in the control group [(1.24 ± 0.22) mmol/L vs. (1.31 ± 0.26) mmol/L, χ2 = 10.462, t = 5.542, 5.429, 2.373, 4.498, 32.865, 17.982 and 2.725, all P < 0.05]. Serum miR-1 and miR-155 expression in patients with ACI gradually increased with the increase of disease severity ( t = 10.212, 13.050, 3.092, 7.027, 3.983 and 4.099, all P < 0.05). The proportion of patients having a history of hypertension in the poor prognosis group was significantly higher than that in the good prognosis group [64.47% (49/76) vs. 42.27% (41/97), χ2 = 8.419, P < 0.05]. Systolic blood pressure, diastolic blood pressure, NIHSS score, serum miR-1 and miR-155 expression in the poor prognosis group were (136.51 ± 12.56) mmHg, (89.53 ± 6.65) mmHg, (7.26 ± 0.58) points, (1.32 ± 0.15), (1.21 ± 0.12), respectively, which were significantly higher than those in the good prognosis group [42.27% (41/97), (132.19 ± 9.32) mmHg, (86.34 ± 5.62) mmHg, (6.44 ± 0.62) points, (1.01 ± 0.07) (0.99 ± 0.05), t = 2.597, 3.418, 8.880, 10.695 and 4.633, all P < 0.05]. The receiver operating characteristic curve (ROC curve) analysis results showed the area under the curve of serum miR-1 and miR-155 expression alone in predicting ACI prognosis was 0.814 (95% CI 0.745-0.884) and 0.839 (95% CI 0.780-0.897), respectively. The area under the curve of miR-1 and miR-155 expression in combination in predicting ACI prognosis was 0.944 (95% CI 0.912-0.976). Logistic regression analysis results showed that increases in admission NIHSS score, miR-1 and miR-155 expression were the risk factors for poor prognosis of ACI ( P < 0.05). Conclusion:miR-1 and miR-155 expression levels are related to the severity of ACI and therefore may be the predictors of poor prognosis of ACI.